Literature DB >> 11556845

The topology of plasminogen binding and activation on the surface of human breast cancer cells.

N M Andronicos1, M Ranson.   

Abstract

The urokinase-dependent activation of plasminogen by breast cancer cells plays an important role in metastasis. We have previously shown that the metastatic breast cancer cell line MDA-MB-231 over-expresses urokinase and binds and efficiently activates plasminogen at the cell surface compared to non-metastatic cells. The aim of this study was to further characterise plasminogen binding and determine the topology of cell surface-bound plasminogen in terms of its potential for activation. The lysine-dependent binding of plasminogen at 4 degrees C to MDA-MB-231 cells was stable and resulted in an activation-susceptible conformation of plasminogen. Topologically, a fraction of bound plasminogen was co-localised with urokinase on the surfaces of MDA-MB-231 cells where it could be activated to plasmin. At 37 degrees C plasmin was rapidly lost from the cell surface. Apart from actin, other candidate plasminogen receptors were either not expressed or did not co-localise with plasminogen at the cell surface. Thus, based on co-localisation with urokinase, plasminogen binding is partitioned into two functional pools on the surface of MDA-MB-231 cells. In conclusion, these results shed further light on the functional organisation of the plasminogen activation cascade on the surface of a metastatic cancer cell. Copyright 2001 Cancer Research Campaign http://www.bjcancer.com.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11556845      PMCID: PMC2375062          DOI: 10.1054/bjoc.2001.2022

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Stopped-flow fluorescence kinetic studies of Glu-plasminogen. Conformational changes triggered by AH-site ligand binding.

Authors:  U Christensen; L Mølgaard
Journal:  FEBS Lett       Date:  1991-01-28       Impact factor: 4.124

Review 2.  Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.

Authors:  M J Duffy; T M Maguire; E W McDermott; N O'Higgins
Journal:  J Surg Oncol       Date:  1999-06       Impact factor: 3.454

3.  Binding of single-chain prourokinase to the urokinase receptor of human U937 cells.

Authors:  M V Cubellis; M L Nolli; G Cassani; F Blasi
Journal:  J Biol Chem       Date:  1986-12-05       Impact factor: 5.157

Review 4.  Cancer invasion and tissue remodeling--cooperation of protease systems and cell types.

Authors:  K Danø; J Rømer; B S Nielsen; S Bjørn; C Pyke; J Rygaard; L R Lund
Journal:  APMIS       Date:  1999-01       Impact factor: 3.205

5.  The human ENO1 gene product (recombinant human alpha-enolase) displays characteristics required for a plasminogen binding protein.

Authors:  N M Andronicos; M Ranson; J Bognacki; M S Baker
Journal:  Biochim Biophys Acta       Date:  1997-01-04

6.  Endothelial cell surface actin serves as a binding site for plasminogen, tissue plasminogen activator and lipoprotein(a).

Authors:  A K Dudani; P R Ganz
Journal:  Br J Haematol       Date:  1996-10       Impact factor: 6.998

7.  Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen.

Authors:  V Ellis; S A Whawell; F Werner; J J Deadman
Journal:  Biochemistry       Date:  1999-01-12       Impact factor: 3.162

8.  Loss of cell viability dramatically elevates cell surface plasminogen binding and activation.

Authors:  M J O'Mullane; M S Baker
Journal:  Exp Cell Res       Date:  1998-07-10       Impact factor: 3.905

9.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.

Authors:  J D Vassalli; D Baccino; D Belin
Journal:  J Cell Biol       Date:  1985-01       Impact factor: 10.539

10.  Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins.

Authors:  M Ranson; N M Andronicos; M J O'Mullane; M S Baker
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

View more
  9 in total

1.  Dissecting mannose 6-phosphate-insulin-like growth factor 2 receptor complexes that control activation and uptake of plasminogen in cells.

Authors:  Vladimir Leksa; Karin Pfisterer; Gabriela Ondrovičová; Brigitte Binder; Silvia Lakatošová; Clemens Donner; Herbert B Schiller; Alexander Zwirzitz; Katarína Mrvová; Vladimir Pevala; Eva Kutejová; Hannes Stockinger
Journal:  J Biol Chem       Date:  2012-05-21       Impact factor: 5.157

2.  Improved pharmacokinetic and biodistribution properties of the selective urokinase inhibitor PAI-2 (SerpinB2) by site-specific PEGylation: implications for drug delivery.

Authors:  Kara Lea Vine; Sergei Lobov; Vineesh Indira Chandran; Nathanial Lachlan Ewart Harris; Marie Ranson
Journal:  Pharm Res       Date:  2014-09-18       Impact factor: 4.200

3.  STIM1/ORAI1-mediated Ca2+ Influx Regulates Enolase-1 Exteriorization.

Authors:  Miroslava Didiasova; Dariusz Zakrzewicz; Viktor Magdolen; Chandran Nagaraj; Zoltán Bálint; Manfred Rohde; Klaus T Preissner; Malgorzata Wygrecka
Journal:  J Biol Chem       Date:  2015-03-24       Impact factor: 5.157

4.  Plasminogen and angiostatin interact with heat shock proteins.

Authors:  Anil K Dudani; Jelica Mehic; Anthony Martyres
Journal:  Mol Cell Biochem       Date:  2007-01-06       Impact factor: 3.842

5.  Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.

Authors:  Gillian E Stillfried; Darren N Saunders; Marie Ranson
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

6.  MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression.

Authors:  Marilyne Kpetemey; Subhamoy Dasgupta; Smrithi Rajendiran; Susobhan Das; Lee D Gibbs; Praveenkumar Shetty; Zygmunt Gryczynski; Jamboor K Vishwanatha
Journal:  Mol Cancer       Date:  2015-08-15       Impact factor: 27.401

7.  Nuclear annexin II negatively regulates growth of LNCaP cells and substitution of ser 11 and 25 to glu prevents nucleo-cytoplasmic shuttling of annexin II.

Authors:  Jie Liu; Christy A Rothermund; Jesus Ayala-Sanmartin; Jamboor K Vishwanatha
Journal:  BMC Biochem       Date:  2003-09-09       Impact factor: 4.059

Review 8.  Double Agent: SPDEF Gene with Both Oncogenic and Tumor-Suppressor Functions in Breast Cancer.

Authors:  Ting Ye; Jia Feng; Xue Wan; Dan Xie; Jinbo Liu
Journal:  Cancer Manag Res       Date:  2020-05-25       Impact factor: 3.989

9.  Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA/NHE1 Active and Single Target-Selective Inhibitors.

Authors:  Benjamin J Buckley; Ashna Kumar; Ashraf Aboelela; Richard S Bujaroski; Xiuju Li; Hiwa Majed; Larry Fliegel; Marie Ranson; Michael J Kelso
Journal:  Int J Mol Sci       Date:  2021-03-15       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.